by Joe Nadglowski, OAC President and CEO For the past 20 years, the Obesity Action Coalition (OAC) has advocated for evidence-based treatments for the disease of obesity. In 2010, OAC began challenging the FDA to take serious action in approving new medicines for obesity treatment. Fast forward to today, and you see we now have
Read Article

FOR IMMEDIATE RELEASE: March 21, 2025 — Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across the healthcare continuum, urging the agency to enforce federal regulations around compounding following the recent resolution
Read Article

The conversation around GLP-1 medications has grown louder in recent years, with these treatments showing great promise for managing obesity. However, challenges like supply shortages and affordability have created barriers for many individuals. In response, patients are turning to compounded GLP-1 medications as an alternative. Leading Conversations on GLP-1 Compounding At the Obesity Action Coalition
Read Article